Clinical Comparison of Different Humidification Strategies During Noninvasive Ventilation With Helmet

NCT ID: NCT02875379

Last Updated: 2019-01-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-02-01

Study Completion Date

2019-01-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background. Non invasive positive pressure ventilation (NIV) is among first line treatments of acute respiratory failure. Several interfaces are available for non-invasive ventilation.Despite full face and oronasal masks are more frequently used, some evidence suggests that helmets may optimize patients' comfort and NIV tolerability.

During NIV, humidification strategies (heat and moisture exchangers HME or heated humidifiers HH) may significantly affect patient's comfort and work of breathing.

Despite physiological data suggested heated humidification as the best strategy during NIV with full face masks, no differences were found in a randomized controlled study assessing the effects of HME or HH on a pragmatic clinical outcome.

However, the higher dead space (i.e. 18 L/min) and rebreathing rate observed during helmet NIV make such results not applicable to this particular setting.

The investigators designed a randomized-crossover trial to assess the effect of four humidification strategies during helmet NIV on patients with acute respiratory failure, in terms of comfort, work of breathing and patient-ventilator interaction.

Methods. All awake, collaborative, hypoxemic patients requiring mechanical ventilation will be considered for the enrollment. Hypercapnic patients (i.e.PaCO2\>45 mmHg) will be excluded.

Each enrolled patient will undergo helmet NIV with all the following humidification strategies in a random order. Each period will last 60 minutes.

* Passive humidification, double tube circuit.
* Heated humification (MR 730, Fisher \& Paykel, Auckland, New Zealand), humidification chamber temperature 33°C.
* Heated humification (MR 730, Fisher \& Paykel, Auckland, New Zealand), humidification chamber temperature 37°C.
* Passive humidification with HME, Y-piece circuit.

Ventilatory settings (Draeger Evita xl or Evita infinity ventilators):

Pressure support ventilation; pressure support=20 cmH20; FiO2 titrated to obtain SpO2 between 92 and 98%; positive end-expiratory pressure=10 cmH2O; maximum inspiratory time 0.9 seconds; inspiratory flow trigger = 2 l/min; expiratory trigger: 30% of the maximum inspiratory flow; pressurization time=0,00 s.

Such settings will be kept unchanged during the whole study period. An oesophageal catheter will be placed and secured to measure oesophageal pressure (Pes) and gastric pressure (Pga) (Nutrivent, Italy): the reliability of the measured pressure will be confirmed with an airway occlusion test during NIV with oronasal mask. Work of breathing will be estimated with the pressure-time product (PTP) of the pleural pressure.

A pneumotachograph (KleisTek) will record flow, airway pressure, Pes and Pga on a dedicated laptop.

At the end of each cycle, the patient will be asked to rate his/her discomfort on a visual analog scale (VAS) modified for ICU patients. The level of dyspnea will be assessed with the Borg dyspnea scale.

The following parameters will be record at the end of each cycle:

Arterial pressure, heart rate, respiratory rate, SpO2, pH, PCO2, PaO2, SaO2. Airway and esophageal pressure signals will be reviewed offline to detect patient-ventilator asynchronies (ineffective efforts, double cycling, premature cycling, delayed cycling) and asynchrony index (number of asynchrony events divided by the total respiratory rate computed as the sum of the number of ventilator cycles (triggered or not) and of wasted efforts) will be computed. The trigger delay will be also measured. The pressurization and depressurization velocity will be assessed with the PTP airway index 300 and 500 (inspiratory and expiratory), as suggested by Ferrone and coworkers. The work of breathing (WOB) for each breath will be estimated by PTPes.

An hygrometer (Dimar SRL, Italy) will measure and record on a dedicated laptop Helmet temperature, relative and absolute humidity.

Primary endpoints: patient's comfort, work of breathing and asynchrony index.

Sample Sizing:

Given the physiological design of the study, the investigators did not make an a priori sample size and plan to enroll 24 patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background Non invasive positive pressure ventilation (NIV) is among first line treatments of acute respiratory failure. In patients with new-onset respiratory failure, NIV was showed to reduce the rate of complications and the length of ICU stay, as compared to invasive mechanical ventilation\[1\] Several interfaces are available for non-invasive ventilation: full face masks, oronasal masks, nasal prongs and helmets\[2\].

Despite full face and oronasal masks are more frequently used, some evidence suggests that helmets may optimize patients' comfort and NIV tolerability. The helmet allows patients' interaction, speech, feeding and does not limit cough. In addition, skin necrosis, gastric distension, or eye irritation are seldom observed during helmet NIV, while may be consequences of long-term treatments with face masks. \[3\] On the contrary, helmet NIV hampers tidal volume monitoring, is contraindicated in hypercapnic patients and requires specific ventilator settings\[4\]. Lastly, when compared to face masks, helmets may increase the work of breathing and worsen patient-ventilator interaction\[5\]\[6\]\[7\].

During NIV, humidification strategies (heat and moisture exchangers HME or heated humidifiers HH) may significantly affect patient's comfort and work of breathing \[8\]\[9\].

Despite physiological data suggested heated humidification as the best strategy during NIV with full face masks\[8\]\[9\], no differences were found in a randomized controlled study assessing the effects of HME or HH on a pragmatic clinical outcome\[10\].

However, the higher dead space (i.e. 18 L/min) and rebreathing rate observed during helmet NIV make such results not applicable to this particular setting.

One only study assessed the effects of a HH during helmet low-flow continuous positive airway pressure on comfort in healthy volunteers\[11\]. Indeed, patients suffering from acute respiratory failure may behave differently, especially in terms of minute ventilation and maximum inspiratory flow.

A recent bench study identified a better patient-ventilator interaction when helmet NIV was provided through a double tube circuit, as compared to the Y-piece system \[12\]. The investigators designed a randomized-crossover trial to assess the effect of four humidification strategies during helmet NIV on patients with acute respiratory failure, in terms of comfort, work of breathing and patient-ventilator interaction.

Methods Design: monocentric, randomized, cross-over trial. Each enrolled patient will undergo helmet NIV with all the following humidification strategies in a random order. Each period will last 60 minutes.

* Passive humidification, double tube circuit.
* Heated humification (MR 730, Fisher \& Paykel, Auckland, New Zealand), humidification chamber temperature 33°C.
* Heated humification (MR 730, Fisher \& Paykel, Auckland, New Zealand), humidification chamber temperature 37°C.
* Passive humidification with HME, Y-piece circuit.

Ventilatory settings (Draeger Evita xl or Evita infinity ventilators):

Pressure support ventilation; pressure support=20 cmH20\[4\]; FiO2 titrated to obtain SpO2 between 92 and 98%; positive end-expiratory pressure=10 cmH2O\[4\]; maximum inspiratory time 0.9 seconds; inspiratory flow trigger = 2 l/min; expiratory trigger: 30% of the maximum inspiratory flow; pressurization time=0,00 s.

Such settings will be kept unchanged during the whole study period. An oesophageal catheter will be placed and secured to measure oesophageal pressure (Pes) and gastric pressure (Pga) (Nutrivent, Italy): the reliability of the measured pressure will be confirmed with an airway occlusion test during NIV with oronasal mask\[13\]. Work of breathing will be estimated with the pressure-time product (PTP) of the pleural pressure\[13\].

A pneumotachograph (KleisTek) will record flow, airway pressure, Pes and Pga on a dedicated laptop.

At the end of each cycle, the patient will be asked to rate his/her discomfort on a visual analog scale (VAS) modified for ICU patients. The level of dyspnea will be assessed with the Borg dyspnea scale\[14\].

The following parameters will be record at the end of each cycle:

Arterial pressure, heart rate, respiratory rate, SpO2, pH, PCO2, PaO2, SaO2. Airway and esophageal pressure signals will be reviewed offline to detect patient-ventilator asynchronies (ineffective efforts, double cycling, premature cycling, delayed cycling) and asynchrony index (number of asynchrony events divided by the total respiratory rate computed as the sum of the number of ventilator cycles (triggered or not) and of wasted efforts) will be computed\[15\]. The trigger delay will be also measured. The pressurization and depressurization velocity will be assessed with the PTP airway index 300 and 500 (inspiratory and expiratory), as suggested by Ferrone and coworkers\[12\]. The work of breathing (WOB) for each breath will be estimated by PTPes.

An hygrometer (Dimar SRL, Italy) will measure and record on a dedicated laptop Helmet temperature, relative and absolute humidity.

End point:

Primary endpoints: patient's comfort, work of breathing and asynchrony index.

Sample Sizing:

Given the physiological design of the study, the investigators did not make an a priori sample size and planned to enroll 24 patients.

Statistical analysis Qualitative data will be expressed as number of events (%) and continuous data as mean ± standard deviation or median \[Interquartile range\]. Comparisons concerning qualitative variables will be performed with the Mc-Namar test. Ordinal qualitative variables or non normal quantitative variables will be compared with the Friedman's Test, the wilcoxon sum of ranks test or the Mann-Whitney test, as appropriate. All analysis will be performed applying a bilateral hypothesis. P ≤ 0.05 will be considered significant. Statistical analysis will be performed with SPSS 20.0.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Respiratory Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HME

Passive humidification with heat and moisture exchanger, Y-piece circuit.

Group Type EXPERIMENTAL

Measurements

Intervention Type PROCEDURE

Measurements of respiratory mechanics and parameters, arterial blood gases and comfort

HH33

Heated humification (MR 730, Fisher \& Paykel, Auckland, New Zealand), humidification chamber temperature 33°C.

Group Type EXPERIMENTAL

Measurements

Intervention Type PROCEDURE

Measurements of respiratory mechanics and parameters, arterial blood gases and comfort

HH37

Heated humification (MR 730, Fisher \& Paykel, Auckland, New Zealand), humidification chamber temperature 33°C.

Group Type EXPERIMENTAL

Measurements

Intervention Type PROCEDURE

Measurements of respiratory mechanics and parameters, arterial blood gases and comfort

NoH

Passive humidification, double tube circuit

Group Type EXPERIMENTAL

Measurements

Intervention Type PROCEDURE

Measurements of respiratory mechanics and parameters, arterial blood gases and comfort

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Measurements

Measurements of respiratory mechanics and parameters, arterial blood gases and comfort

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Awake and collaborative patients
* Age\>18 years
* Need for noninvasive mechanical ventilation
* Informed consent

Exclusion Criteria

* Cardiopulmonary resuscitation
* Haemodynamic instability
* Coma
* Asma
* Hypercapnia (paCO2\>45 mmHg)
* Recent gastric or abdominal surgery
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Catholic University of the Sacred Heart

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Massimo Antonelli

M.D. Full Professor of Anesthesiology and Intensive Care. Head of the department of Anesthesiology and Intensive Care medicine

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

General ICU, A. Gemelli hospital

Rome, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

References

Explore related publications, articles, or registry entries linked to this study.

Bongiovanni F, Grieco DL, Anzellotti GM, Menga LS, Michi T, Cesarano M, Raggi V, De Bartolomeo C, Mura B, Mercurio G, D'Arrigo S, Bello G, Maviglia R, Pennisi MA, Antonelli M. Gas conditioning during helmet noninvasive ventilation: effect on comfort, gas exchange, inspiratory effort, transpulmonary pressure and patient-ventilator interaction. Ann Intensive Care. 2021 Dec 24;11(1):184. doi: 10.1186/s13613-021-00972-9.

Reference Type DERIVED
PMID: 34952962 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

11491/15

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Helmet NIV in Acute Respiratory Failure
NCT05022173 ACTIVE_NOT_RECRUITING NA